The New New Enterprise Associates 13 Lp Holding in Roka Bioscience, Inc
New Enterprise Associates 13 Lp filed with the SEC SC 13D/A form for Roka Bioscience, Inc. The form can be accessed here: 000107261316000939. As reported in New Enterprise Associates 13 Lp’s form, the filler as of late owns 37.9% or 8,941,762 shares of the -company.
Roka Bioscience, Inc stake is a new one for the and it was filed because of activity on September 21, 2016. We feel this shows New Enterprise Associates 13 Lp’s positive view for the stock.
Reasons Why New Enterprise Associates 13 Lp Bought – Roka Bioscience, Inc Stock
Purpose of Transaction
NEA 13 acquired the NEA 13 Securities for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 13 and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in:
|(a)||The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;|
|(b)||An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;|
|(c)||A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;|
|(d)||Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;|
|(e)||Any material change in the present capitalization or dividend policy of the Issuer;|
|(f)||Any other material change in the Issuer’s business or corporate structure;|
|(g)||Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;|
1 See the Schedule 13D or 13G (or an amendment thereto to the extent any material changes in the facts set forth in any Schedule 13D or 13G previously filed by any other Shareholder has occurred) filed, or that the Reporting Persons anticipate will be filed, separately by each Shareholder, which includes, or will include, information regarding the other Shareholder’s number of shares of Common Stock of the Issuer, jurisdiction of organization, principal business and address of principal office.
|13D||Page16 of23 Pages|
|(h)||Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;|
|(i)||A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section12(g)(4) of the Securities Exchange Act of 1934; or|
|(j)||Any action similar to any of those enumerated above.|
Roka Bioscience, Inc Institutional Sentiment
Latest Security and Exchange filings show 26 investors own Roka Bioscience, Inc. The institutional ownership in Q3 2015 is low, at 71.70% of the outstanding shares. This is decreased by 584945 the total institutional shares. 12820851 were the shares owned by these institutional investors. In total 1 funds opened new Roka Bioscience, Inc stakes, 4 increased stakes. There were 9 that closed positions and 7 reduced them.
Tpg Group Holdings Sbs Advisors Inc is an institutional investor bullish on Roka Bioscience, Inc, owning 2989282 shares as of Q3 2015 for 0.03% of its portfolio. Birchview Capital Lp owns 152307 shares or 0.21% of its portfolio. NY Aisling Capital Llc have 0.28% of their stock portfolio for 811886 shares. Further, Nea Management Company Llc reported stake worth 0.41% of its US stock portfolio. The NY Drill Craig A owns 1600000 shares. Roka Bioscience, Inc is 4.44% of the manager’s US portfolio.
Roka Bioscience, Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.
SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.
Insitutional Activity: The institutional sentiment increased to 0.5 in Q2 2016. Its up 0.23, from 0.27 in 2016Q1. The ratio is positive, as 4 funds sold all Roka Bioscience Inc shares owned while 2 reduced positions. 1 funds bought stakes while 2 increased positions. They now own 11.75 million shares or 4.44% less from 12.30 million shares in 2016Q1.
Drill Craig A holds 1.8% of its portfolio in Roka Bioscience Inc for 1.60 million shares. Birchview Capital Lp owns 252,307 shares or 0.1% of their US portfolio. Moreover, Nea Management Company Llc has 0.1% invested in the company for 3.22 million shares. The New York-based Orbimed Advisors Llc has invested 0.02% in the stock. Tpg Group Holdings (Sbs) Advisors Inc., a Texas-based fund reported 2.99 million shares.
Analysts await Roka Bioscience Inc (NASDAQ:ROKA) to report earnings on November, 9.
The stock decreased 3.31% or $0.022 on September 28, hitting $0.633. Roka Bioscience Inc (NASDAQ:ROKA) has declined 19.87% since February 25, 2016 and is downtrending. It has underperformed by 31.13% the S&P500.
Out of 2 analysts covering Roka Bioscience (NASDAQ:ROKA), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. $2 is the highest target while $1 is the lowest. The $1.50 average target is 136.97% above today’s ($0.633) stock price. Roka Bioscience has been the topic of 3 analyst reports since November 12, 2015 according to StockzIntelligence Inc. Leerink Swann downgraded the stock on March 7 to “Market Perform” rating.
According to Zacks Investment Research, “Roka Bioscience, Inc. is a molecular diagnostics company. It is focused on developing and commercializing advanced testing solutions for the food safety testing market. Roka provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin-producing E. coli, and Listeria monocytogenes, as well as related consumable supplies. Roka Bioscience, Inc. is headquartered in Warren, New Jersey.”
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.